CLEAN VERSION OF AMENDED SPECIFICATION PARAGRAPHS

The paragraph beginning at page 1, line 4 is amended as follows:

This application is a continuation application of U.S. application Serial No. 09/276,625, which is a continuation-in-part of, and claims priority of invention under 35 U.S.C. § 119(e) from, U.S. application Serial No. 60/086,166, filed May 20, 1998, the disclosure of which is incorporated by reference herein.

The paragraph beginning at page 19, line 16 is amended as follows:

Figure 19. Application of rAAV circular concatamers to deliver vectors with large gene inserts. Panel A depicts two rAAV vectors encoding two halves of a cDNA (red) flanked by splice site consensus sequences (brown). Panel B depicts one potential type of intermolecular concatamer following co-infection of cells with the independent vectors shown in panel A. Full length transgene mRNA can then be produced by splicing between these two vector encoded sequences within circular concatamers.

The paragraph beginning at page 79, line 29 is amended as follows:

Intermolecular recombination of rAAV genomes to form single circular episomes may be particularly useful for gene therapy. For example, large regulatory elements and genes beyond the packaging capacity of rAAV may become linked after co-infecting tissue with two independent vectors (Figure 19). This strategy could also involve splicing of transcripts from vectors encoding two independent regions of a gene which are brought together to form an intact splicing unit by circular concatamerization.